Francesca Grilli, Sadman Sakib, Fabio Variola, Shan Zou
{"title":"Graphene Oxide-Based Gene Modulation in Preferential Elimination of Lung Cancer Cells in a 3D Tumor Microenvironment Model","authors":"Francesca Grilli, Sadman Sakib, Fabio Variola, Shan Zou","doi":"10.1002/anbr.202500028","DOIUrl":null,"url":null,"abstract":"<p>Lung cancer remains the leading cause of cancer-related mortality worldwide, owing to its aggressive nature, late-stage diagnosis, and resistance to conventional therapies. Gene therapy offers a promising alternative by modulating specific genetic pathways to target cancer cells while sparing healthy ones. This study investigates the potential of chemically functionalized nanoscale graphene oxide (GO) as carriers for delivering therapeutic genes in a 3D tumor microenvironment (TME) model, incorporating lung cancer cells, human lung fibroblasts, and macrophages in a Matrigel-collagen matrix to mimic the structural properties and immune functions. These therapeutic genes, including small interfering RNAs and plasmid DNAs, regulate immune evasion markers (CD47 and CD24) and apoptosis-inducing proteins (ANT1). GO nanocarriers demonstrate preferential uptake in cancer cells, achieving transfection and gene modulation within the TME model. The individual delivery of genes downregulates cancer markers and induces ANT1 expression, resulting in lung cancer cell elimination. Co-delivery of CD47_siRNA and ANT1_pDNA produces synergistic efficacy, enhancing cancer cell elimination. These findings highlight the potential of GO-based gene therapies as a targeted and effective approach for lung cancer treatment, setting the stage for in vivo validation and clinical translation.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 7","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500028","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202500028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, owing to its aggressive nature, late-stage diagnosis, and resistance to conventional therapies. Gene therapy offers a promising alternative by modulating specific genetic pathways to target cancer cells while sparing healthy ones. This study investigates the potential of chemically functionalized nanoscale graphene oxide (GO) as carriers for delivering therapeutic genes in a 3D tumor microenvironment (TME) model, incorporating lung cancer cells, human lung fibroblasts, and macrophages in a Matrigel-collagen matrix to mimic the structural properties and immune functions. These therapeutic genes, including small interfering RNAs and plasmid DNAs, regulate immune evasion markers (CD47 and CD24) and apoptosis-inducing proteins (ANT1). GO nanocarriers demonstrate preferential uptake in cancer cells, achieving transfection and gene modulation within the TME model. The individual delivery of genes downregulates cancer markers and induces ANT1 expression, resulting in lung cancer cell elimination. Co-delivery of CD47_siRNA and ANT1_pDNA produces synergistic efficacy, enhancing cancer cell elimination. These findings highlight the potential of GO-based gene therapies as a targeted and effective approach for lung cancer treatment, setting the stage for in vivo validation and clinical translation.
期刊介绍：
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
